FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108943> ?p ?o ?g. }

• W4310108943 endingPage "8929" @default.
• W4310108943 startingPage "8929" @default.
• W4310108943 abstract "Background: Bone marrow biopsy on day 14 of induction therapy for patients with acute myeloid leukemia (AML) is a common practice to determine whether re-induction therapy is warranted. A second bone marrow biopsy on day 28 is performed to assess remission status. We desired to explore what proportion of patients received bone marrow biopsies on day 14 at our institution, how many of these biopsies had disease present, and how these results affected clinical decision-making regarding whether re-induction was pursued. We compared outcomes of patients that received re-induction therapy based on bone marrow biopsies on day 14 versus on day 28 or later. Methods: A single-center retrospective study was performed detailing 252 AML patients that underwent induction therapy between December 1999 and December 2021. Pathology reports were reviewed to document the disease status at day 14 post induction with 7+3” regimen. Response to induction therapy was defined per standard definitions. Statistics are descriptive. Results: Of the 252 patients, 95 had bone marrow biopsies on day 14. Of these patients, 80 had adequate bone marrow sampling to quantify blast cell percentage. Thirty-four of these patients had no detectable blast cells while 46 had some evidence of disease. Of these 46 patients five (11%) had disease but less than 5% blast cells, 19 (41%) had between 5 and 20% blasts, and 22 (48%) had greater than 20% blasts. Of the 46 patients that still showed some evidence of disease, 7 (15.2%) underwent re-induction. This accounted for 2.78% of the total number of patients. One patient was re-induced with less than 5% blasts, 4 with between 5-20% blasts, and 2 with greater than 20% blasts. The rate of complete remission in patients who received re-induction therapy was 50% for day 14 patients and 46.7% for day 28 or later patients (P<0.43). Of the 15 patients with <20% blasts, 14 had a repeat biopsy and 9 (64.3%) went into remission without re-induction therapy. In the 20 patients with >20% blasts, 18 had a repeat biopsy and 5 (27.8%) went into remission without re-induction. Conclusions: Even in patients that had evidence of disease on day 14 bone marrow biopsy only a fraction received re-induction therapy. The rates of complete remission were very similar between patients who underwent re-induction based on day 14 bone marrow biopsy results compared to day 28 or later. Increasing availability of lower intensive regimens might lead to more treatment options and further reduce the need for re-induction based on day 14 disease assessment. Future trials need to reevaluate the need for routine evaluation of disease burden on around day 14 post induction therapy." @default.
• W4310108943 created "2022-11-30" @default.
• W4310108943 creator A5004750202 @default.
• W4310108943 creator A5034221305 @default.
• W4310108943 creator A5039582413 @default.
• W4310108943 creator A5052119078 @default.
• W4310108943 creator A5059747862 @default.
• W4310108943 creator A5062561099 @default.
• W4310108943 creator A5083051710 @default.
• W4310108943 date "2022-11-15" @default.
• W4310108943 modified "2023-10-18" @default.
• W4310108943 title "Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy" @default.
• W4310108943 doi "https://doi.org/10.1182/blood-2022-164963" @default.
• W4310108943 hasPublicationYear "2022" @default.
• W4310108943 type Work @default.
• W4310108943 citedByCount "0" @default.
• W4310108943 crossrefType "journal-article" @default.
• W4310108943 hasAuthorship W4310108943A5004750202 @default.
• W4310108943 hasAuthorship W4310108943A5034221305 @default.
• W4310108943 hasAuthorship W4310108943A5039582413 @default.
• W4310108943 hasAuthorship W4310108943A5052119078 @default.
• W4310108943 hasAuthorship W4310108943A5059747862 @default.
• W4310108943 hasAuthorship W4310108943A5062561099 @default.
• W4310108943 hasAuthorship W4310108943A5083051710 @default.
• W4310108943 hasBestOaLocation W43101089431 @default.
• W4310108943 hasConcept C126322002 @default.
• W4310108943 hasConcept C2775934546 @default.
• W4310108943 hasConcept C2776611710 @default.
• W4310108943 hasConcept C2776694085 @default.
• W4310108943 hasConcept C2778336483 @default.
• W4310108943 hasConcept C2778461978 @default.
• W4310108943 hasConcept C2778729363 @default.
• W4310108943 hasConcept C2779282312 @default.
• W4310108943 hasConcept C2780007613 @default.
• W4310108943 hasConcept C71924100 @default.
• W4310108943 hasConceptScore W4310108943C126322002 @default.
• W4310108943 hasConceptScore W4310108943C2775934546 @default.
• W4310108943 hasConceptScore W4310108943C2776611710 @default.
• W4310108943 hasConceptScore W4310108943C2776694085 @default.
• W4310108943 hasConceptScore W4310108943C2778336483 @default.
• W4310108943 hasConceptScore W4310108943C2778461978 @default.
• W4310108943 hasConceptScore W4310108943C2778729363 @default.
• W4310108943 hasConceptScore W4310108943C2779282312 @default.
• W4310108943 hasConceptScore W4310108943C2780007613 @default.
• W4310108943 hasConceptScore W4310108943C71924100 @default.
• W4310108943 hasIssue "Supplement 1" @default.
• W4310108943 hasLocation W43101089431 @default.
• W4310108943 hasOpenAccess W4310108943 @default.
• W4310108943 hasPrimaryLocation W43101089431 @default.
• W4310108943 hasRelatedWork W148891655 @default.
• W4310108943 hasRelatedWork W2121159001 @default.
• W4310108943 hasRelatedWork W2345875528 @default.
• W4310108943 hasRelatedWork W2360105106 @default.
• W4310108943 hasRelatedWork W2374834777 @default.
• W4310108943 hasRelatedWork W2407255173 @default.
• W4310108943 hasRelatedWork W2559501116 @default.
• W4310108943 hasRelatedWork W2936131736 @default.
• W4310108943 hasRelatedWork W3096241657 @default.
• W4310108943 hasRelatedWork W42711520 @default.
• W4310108943 hasVolume "140" @default.
• W4310108943 isParatext "false" @default.
• W4310108943 isRetracted "false" @default.
• W4310108943 workType "article" @default.